{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:02:04Z","timestamp":1776088924284,"version":"3.50.1"},"reference-count":34,"publisher":"ARAN Ediciones","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutr Hosp"],"published-print":{"date-parts":[[2026]]},"DOI":"10.20960\/nh.05970","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:22:24Z","timestamp":1776086544000},"source":"Crossref","is-referenced-by-count":0,"title":["Analysis of PNPLA3, TM6SF2 and GCKR gene polymorphisms in patients with metabolic dysfunction\u2013associated steatohepatitis treated with probiotics \u2012 An exploratory study"],"prefix":"10.20960","author":[{"given":"Carolina Bortolin","family":"Beskow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raif Gregorio","family":"Nasre-Nasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Souza","family":"Silva-Sperb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Crispim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Cremonese","family":"Filippi-Chiela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valesca","family":"Dall'Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8588","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77(4):1335-47.","DOI":"10.1097\/HEP.0000000000000004"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79(6):1542-56.","DOI":"10.1097\/HEP.0000000000000696"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sookoian S, Pirola CJ. Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics. Semin Liver Dis 2019;39(2):124-40.","DOI":"10.1055\/s-0039-1679920"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 2022;22(1):63.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Carpi RZ, Barbalho SM, Sloan KP, et al. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review. Int J Mol Sci 2022;23(15):8805.","DOI":"10.3390\/ijms23158805"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51(4):1209-17.","DOI":"10.1002\/hep.23622"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46(4):352-6.","DOI":"10.1038\/ng.2901"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309.","DOI":"10.1038\/ncomms5309"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Sookoian S, Casta\u00f1o GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015;61(2):515-25.","DOI":"10.1002\/hep.27556"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61(2):506-14.","DOI":"10.1002\/hep.27490"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013;19(29):5219-38.","DOI":"10.2174\/13816128113199990381"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Perez-Diaz-Del-Campo N, Dileo E, Castelnuovo G, et al. A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease. Clin Nutr 2023;42(11):2181-7.","DOI":"10.1016\/j.clnu.2023.09.022"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Shen J, Wong GL, Chan HL, et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2015;30(1):139-46.","DOI":"10.1111\/jgh.12656"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Silva-Sperb AS, Moraes HA, Barcelos STA, et al. Probiotic supplementation for 24\u2009weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial. Front Nutr 2024;11:1362694.","DOI":"10.3389\/fnut.2024.1362694"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328-57.","DOI":"10.1002\/hep.29367"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 2008;61(7):634-45.","DOI":"10.1016\/j.jclinepi.2007.12.011"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Alvares-da-Silva MR, Ivancovsky-Wajcman D, Oliveira CP, et al. High red meat consumption among PNPLA3 polymorphism carriers is associated with NAFLD in a multi-center cross-sectional study. Eur J Clin Nutr 2024;78(5):442-8.","DOI":"10.1038\/s41430-024-01416-w"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Lisboa QC, Nardelli MJ, Pereira PA, et al. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol 2020;12(10):792-806.","DOI":"10.4254\/wjh.v12.i10.792"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Mazo DF, Malta FM, Stefano JT, et al. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Ann Hepatol 2019;18(3):466-71.","DOI":"10.1016\/j.aohep.2018.10.004"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Liu Z, Zhang Y, Graham S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol 2020;73(2):263-76.","DOI":"10.1016\/j.jhep.2020.03.006"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology 2015;62(6):1742-56.","DOI":"10.1002\/hep.28142"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014;46(4):345-51.","DOI":"10.1038\/ng.2926"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Gruzdev SK, Podoprigora IV, Gizinger OA. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets. Arch Microbiol 2024;206(2):62.","DOI":"10.1007\/s00203-023-03752-0"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014;146(6):1513-24.","DOI":"10.1053\/j.gastro.2014.01.020"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial. J Gastrointestin Liver Dis 2018;27(1):41-9.","DOI":"10.15403\/jgld.2014.1121.271.kby"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ahn SB, Jun DW, Kang BK, et al. Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9(1):5688.","DOI":"10.1038\/s41598-019-42059-3"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Chen Y, Feng R, Yang X, et al. Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr 2019;109(6):1611\u20109.","DOI":"10.1093\/ajcn\/nqy358"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Chong PL, Laight D, Aspinall RJ, et al. A randomised placebo controlled trial of VSL#3. BMC Gastroenterol 2021;21(1):144.","DOI":"10.1186\/s12876-021-01660-5"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wang H, Li S, Li H, et al. Mechanism of Probiotic VSL#3 Inhibiting NF-\u03baB and TNF-\u03b1 on Colitis through TLR4-NF-\u03baB Signal Pathway. Iran J Public Health 2019;48(7):1292-300.","DOI":"10.18502\/ijph.v48i7.2953"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zain SM, Mohamed Z, Mohamed R. Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 2015;30(1):21-7.","DOI":"10.1111\/jgh.12714"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wang Z, Li W, Lyu Z, et al. Effects of probiotic\/prebiotic\/synbiotic supplementation on blood glucose profiles: a systematic review and meta-analysis of randomized controlled trials. Public Health 2022;210:149-159.","DOI":"10.1016\/j.puhe.2022.06.012"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Chen Y, Feng R, Yang X, et al. Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr 2019;109(6):1611-9.","DOI":"10.1093\/ajcn\/nqy358"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Pagano AP, Sicchieri JMF, Schiavoni IL, et al. Phase angle as a severity indicator for liver diseases. Nutrition 2020;70:110607.","DOI":"10.1016\/j.nut.2019.110607"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Norman K, Stob\u00e4us N, Pirlich M, et al. Bioelectrical phase angle and impedance vector analysis--clinical relevance and applicability of impedance parameters. Clin Nutr 2012;31(6):854-61.","DOI":"10.1016\/j.clnu.2012.05.008"}],"container-title":["Nutrici\u00f3n Hospitalaria"],"original-title":[],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:22:54Z","timestamp":1776086574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nutricionhospitalaria.org\/articles\/05970\/show"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"URL":"https:\/\/doi.org\/10.20960\/nh.05970","relation":{},"ISSN":["1699-5198","0212-1611"],"issn-type":[{"value":"1699-5198","type":"electronic"},{"value":"0212-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}